{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang J"],"funding":["Jiaxing Science and Technology Plan Project","Research Funding for Lin He’s Academician Workstation of New Medicine and Clinical Translation"],"pagination":["300060520947937"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7436784"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(8)"],"pubmed_abstract":["<h4>Objective</h4>The aim of the study was to quantitatively assess the association of metallothionein 2A (<i>MT2A</i>) polymorphisms rs28366003 and rs1610216 with cancer risk.<h4>Methods</h4>Crude odd ratios (OR) with 95% confidence intervals (CI) were used to estimate associations of the polymorphisms with cancer risk.<h4>Results</h4>Six eligible case-control studies with 1899 cases and 2437 controls focused on rs28366003, and three of those six studies, with 548 cases and 926 controls, additionally focused on rs1610216. Pooled analysis showed that <i>MT2A</i> rs28366003 and rs1610216 were associated with cancer risk: (AG + GG) vs. AA, OR = 2.67; GG vs. (AG + AA), OR = 5.97; GG vs. AA, OR = 6.80; AG vs. AA, OR = 2.46; G vs. A, OR = 2.67 for rs28366003; and CC vs. (TC+TT), OR = 2.51; CC vs. TT, OR = 2.42 for rs1610216. Subgroup analysis based on ethnicity showed a significant association of rs28366003 with cancer risk in Asian and Caucasian populations. However, a significant association of rs1610216 with cancer risk was found only in the Asian population.<h4>Conclusion</h4><i>MT2A</i> rs28366003 and rs1610216 polymorphisms were associated with cancer risk and might serve as genetic biomarkers for predicting cancer risk. However, larger studies are needed to confirm these findings."],"journal":["The Journal of international medical research"],"pubmed_title":["Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk."],"pmcid":["PMC7436784"],"funding_grant_id":["2020AY10029,2019AY32005 and 2020AY30001","No: 81702452"],"pubmed_authors":["Ren W","Wu L","Zhao W","Ai L","Wang J","Huang P"],"additional_accession":[]},"is_claimable":false,"name":"Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk.","description":"<h4>Objective</h4>The aim of the study was to quantitatively assess the association of metallothionein 2A (<i>MT2A</i>) polymorphisms rs28366003 and rs1610216 with cancer risk.<h4>Methods</h4>Crude odd ratios (OR) with 95% confidence intervals (CI) were used to estimate associations of the polymorphisms with cancer risk.<h4>Results</h4>Six eligible case-control studies with 1899 cases and 2437 controls focused on rs28366003, and three of those six studies, with 548 cases and 926 controls, additionally focused on rs1610216. Pooled analysis showed that <i>MT2A</i> rs28366003 and rs1610216 were associated with cancer risk: (AG + GG) vs. AA, OR = 2.67; GG vs. (AG + AA), OR = 5.97; GG vs. AA, OR = 6.80; AG vs. AA, OR = 2.46; G vs. A, OR = 2.67 for rs28366003; and CC vs. (TC+TT), OR = 2.51; CC vs. TT, OR = 2.42 for rs1610216. Subgroup analysis based on ethnicity showed a significant association of rs28366003 with cancer risk in Asian and Caucasian populations. However, a significant association of rs1610216 with cancer risk was found only in the Asian population.<h4>Conclusion</h4><i>MT2A</i> rs28366003 and rs1610216 polymorphisms were associated with cancer risk and might serve as genetic biomarkers for predicting cancer risk. However, larger studies are needed to confirm these findings.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2024-11-13T00:53:29.221Z","creation":"2020-09-05T07:11:58Z"},"accession":"S-EPMC7436784","cross_references":{"pubmed":["32809904"],"doi":["10.1177/0300060520947937"]}}